EKF Diagnostics Holdings

Trellus Health Inc. specializes in providing a digital health solution tailored for managing complex chronic conditions, with an initial focus on Inflammatory Bowel Diseases, such as Crohn's Disease and ulcerative colitis. Founded in 2020 and headquartered in White Plains, New York, the company utilizes a connected care platform that integrates both clinical and behavioral health services to enhance patient outcomes and reduce healthcare costs. Their approach is grounded in the GRITT resilience-based methodology, which is scientifically validated, and delivered through the proprietary TrellusElevate technology platform. This comprehensive, telehealth-based model coordinates access to high-quality clinical care, aiming to serve patients, employers, and the broader healthcare system effectively. Trellus Health also maintains an office in Cardiff, United Kingdom, and envisions expanding its services to address various chronic conditions beyond its current focus.

DiaSpect Medical AB develops hemoglobin measurement systems.

Selah Genomics Inc. is a clinical diagnostic specialist based in Greenville, South Carolina, that provides advanced molecular and genomic diagnostic services to healthcare providers and the pharmaceutical industry in the United States. Founded in 2006 and originally known as Lab21 Inc., the company focuses on enhancing diagnostic testing services particularly in women's health and personalized cancer treatment. Its offerings include molecular diagnostic testing, assay validation, and genomic profiling, which assist clinicians in treating and monitoring patients. Selah Genomics specializes in various areas such as next-generation sequencing, companion diagnostics, RNA sequencing, targeted sequencing, and bioinformatics. The company's services are designed to support early-stage drug development, clinical trials, and regulatory processes, thereby contributing to improved patient outcomes.

Separation Technology Inc. provides centrifugation solutions to the laboratory marketplace.

360 Genomics Ltd. develops molecular diagnostic technologies for the detection of mutations in key oncogenes.

tanbio Laboratory, L.P. manufactures medical devices and products for in-vitro diagnostic companies in the clinical laboratory market.

Argutus Medical is a world leader in developing and manufacturing specialised organ injury assays. Argutus Medical primarily focuses on developing ELISA tests and lateral flow rapid test devices for detection of acute kidney injury (Nephrotoxicity) and acute liver injury (Hepatotoxicity). Argutus also manufactures a range of other assays including OxyDNA, a unique test for oxidative DNA damage (Genotoxicity). Argutus Medical was previously part of Biotrin International before branching out in 2008. In 2010 Argutus Medical was acquired by EKF Diagnostics Holdings plc, a rapidly growing global health care company. Being part of EKF Diagnostics has allowed Argutus Medical to continue to focus on biomarker discovery and development of novel biomarker assays from their facility in Dublin, Ireland.

Quotient Diagnostics Ltd. develops a testing technology for the diagnosis, treatment, and management of diabetes and associated diseases.